Table 4.
Unadjusted Comparisons of Patient Characteristics For New Allopurinol Users Stratified by sUA Goal versus Not at sUA Goal
| Patient Characteristics | Total | sUA at Goal (<6mg/dl) | sUA not at Goal (≥6mg/dl) | P Value* |
|---|---|---|---|---|
| N= 9,581a | N= 3,078 | N= 6,503 | ||
| Male (vs. female) n, (%) | 7,218 (75.3) | 2,149 (69.8) | 5,069 (77.9) | <.0001* |
| Patient Age Groups, years, n(%) | <.0001* | |||
| <55 | 3,462 (36.1) | 782 (25.4) | 2,680 (41.2) | |
| 55-64 | 3,923 (40.9) | 1,086 (35.3) | 2,837 (43.6) | |
| ≥65 | 2,196 (22.9) | 1,209 (39.3) | 987 (15.2) | |
| Race/Ethnicity, n(%) | <.0001* | |||
| Caucasian | 4,762 (49.7) | 1,622 (52.7) | 3,140 (48.3) | |
| African American | 1,246 (13.0) | 442 (14.4) | 804 (12.4) | |
| Hispanic | 1,471 (15.4) | 406 (13.2) | 1,065 (16.4) | |
| Asian/Pacific Islander | 78 (0.8) | 12 (0.4) | 66 (1.0) | |
| Other | 2,024 (21.1) | 596 (19.4) | 1,428 (22.0) | |
| Comorbidities, n (%) | ||||
| Hypertension | 7,743 (80.8) | 2,505 (81.4) | 5,238 (80.5) | 0.78 |
| Myocardial infarction | 823 (8.6) | 219 (7.1) | 604 (9.3) | 0.77 |
| Congestive heart failure | 1,055 (11.0) | 254 (8.3) | 801 (12.3) | 0.0003* |
| Diabetes | 2,850 (29.7) | 858 (27.9) | 1,992 (30.6) | 0.07 |
| Other Covariates | ||||
| Baseline GFR, ml/min, mean SD | 60.5±18.0 | 61.6±15.9 | 55.2±18.8 | <.0001* |
| Diuretic use, n(%) | 4,798 (50.1) | 1,584 (51.5) | 3,214 (49.4) | 0.25 |
| Use of baseline anti-inflammatory, n(%) | 5,357 (55.9) | 1,272 (41.3) | 4,085 (62.8) | <.0001* |
| Rheumatologist as initial prescriber, n(%) | 757 (7.9) | 412 (13.4) | 345 (5.3) | <.0001* |
| Allopurinol Adherence (PDC ≥80) | 4,767 (49.8) | 2,001 (65) | 2,766 (42.5) | 0.004* |
| Starting Allopurinol Total Dose, mg/day, n(%) | ||||
| ≤ 100 | 5,070 (52.9) | 699 (22.7) | 4,371 (67.2) | <.0001* |
| >100 to < 300 | 1,995 (20.8) | 1,217 (39.5) | 778 (12.0) | <.0001* |
| ≥ 300 | 2,516 (26.3) | 1,162 (37.8) | 1,354 (20.8) | <.0001* |
| Allopurinol Dose Adjustment | ||||
| Dose escalation | 2992 (31.2) | 1797 (58.3) | 1195 (18.4) | <0.002* |
a
sUA was evaluated for patients that had a baseline and follow-up sUA level anytime during observation (N=9,581). The last sUA level was taken for each patient during follow-up period.
*
P value was set at <0.05 for statistical significance.
Serum urate (sUA); glomerular filtration rate (GFR); standard deviation (SD).